Fatigue, quality of life and metabolic changes in men treated with first-line enzalutamide versus abiraterone plus prednisolone for metastatic castration-resistant prostate cancer (HEAT): a randomised trial protocol

Fatigue, quality of life and metabolic changes in men treated with first-line enzalutamide versus abiraterone plus prednisolone for metastatic castration-resistant prostate cancer (HEAT): a randomised trial protocol

Introduction Enzalutamide and abiraterone acetate plus prednisolone (AAP) are used in combination with androgen-deprivation therapy to further suppress the androgen stimulation of metastatic castration-resistant prostate cancer (mCRPC). First-line mCRPC treatment with enzalutamide and AAP yields sim...

Full description

Bibliographic Details
Main Authors: Klara Kvorning Ternov, Jens Sønksen, Mikkel Fode, Henriette Lindberg, Caroline Michaela Kistorp, Rasmus Bisbjerg, Ganesh Palapattu, Peter Busch Østergren
Format: Article
Language:English
Published: BMJ Publishing Group 2019-09-01
Series:BMJ Open
Online Access:https://bmjopen.bmj.com/content/9/9/e030218.full

Internet

https://bmjopen.bmj.com/content/9/9/e030218.full

Similar Items